JPRN-UMIN000006965
Completed
Phase 2
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who presented well-defined taxane resistance - Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who presented well-defined taxane resistance
Saitama Breast Cancer Clinical Study Group (SBCCSG)0 sites52 target enrollmentJanuary 4, 2012
ConditionsBreast Cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- Saitama Breast Cancer Clinical Study Group (SBCCSG)
- Enrollment
- 52
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)having systemic infection with a fever of 38 degrees or more 2\)pleural effusion, ascites, or pericardial fluid requiring drainage 3\)brain metastasis with clinical symptoms 4\)patient with following serious complication ischaemic heart disease or heart disease such as arrhythmia not controllable by treatment myocardial infarction \< 6 months prior to study entry hepatic cirrhosis interstitial pneumonia or pulmonary fibrosis bleeding tendency 5\)having active double cancer 6\)HER2 over\-expressed 7\)pregnancy, breast\-feeding or women with childbearing potential 8\)judged by the investigator not to be appropriate for the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
A phase II study of eribulin monotherapy for advanced extramammary Paget's diseaseJPRN-jRCT2011220022Yanagi Teruki18
Completed
Phase 2
A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancercolorectal cancerJPRN-UMIN000031221Aichi Cancer Center Hospital30
Recruiting
Not Applicable
Exploratory clinical study of eribulin followed by taxane for metastatic breast cancer patientsMetastatic breast cancerJPRN-UMIN000027527Yamaguchi University Graduate School of Medicine30
Completed
Phase 2
Phase II trial of eribulin in patients with recurrent glioblastoma (ENIGMA)GlioblastomaJPRN-UMIN000030359ational Cancer Center38
Completed
Not Applicable
A Phase II Study of Eribulin Evaluating Efficacy and Safety as first or secondary line chemotherapy for advanced or metastatic breast cancer without HER2 overexpressingAdvanced or metastatic breast cancerJPRN-UMIN000009568General and Gastroenterological Surgery, Osaka Medical College35